Abstract
Q Therapeutics is aiming to begin human trials for targeted transplantation of astrocyte precursor cells to slow the loss of respiratory function in ALS, building on animal proof of concept published by a team of collaborators from Johns Hopkins and Invitrogen Corp.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
